Home Newsfeeds Oppenheimer Maintains Outperform on Shopify. Price adjusts to $50.

Oppenheimer Maintains Outperform on Shopify. Price adjusts to $50.

Oppenheimer analyst Brian Schwartz maintains Shopify (NYSE:SHOP) with a Outperform. Price adjusts to $50

byBenzinga Newsdesk

July 7, 2022

1 minute read

Oppenheimer analyst Brian Schwartz maintains Shopify (NYSE:SHOP) with a Outperform. Price adjusts to $50

News

GitLab Introduces TeamOps, A New Practice For All Work Environments – Remote, Hybrid And In-Office

By Benzinga Newsdesk

October 5, 9:02 AM

SAN FRANCISCO, Oct. 05, 2022 (GLOBE NEWSWIRE) -- All-Remote – Today, GitLab Inc. (NASDAQ:GTLB), provider of The One DevOps Platform, introduced TeamOps, a results-focused management

GTLB

Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $58

By Benzinga Newsdesk

November 2, 9:53 AM

Barclays analyst Peter Lawson maintains Blueprint Medicines (NASDAQ:BPMC) with a Equal-Weight and lowers the price target from $70 to $58.

BPMC

Analyst Ratings

What 10 Analyst Ratings Have To Say About Revolve Gr

By Benzinga Insights

December 14, 1:00 PM

Analysts have provided the following ratings for Revolve Gr (NYSE:RVLV) within the last quarter: Bullish Somewhat Bullish Indifferent…

RVLV

News

Moonlake Immunotherapeutics Announced Landmark Phase 2 Results For Nanobody Sonelokimab In Active Psoriatic Arthritis; Primary Endpoint; Key Secondary Endpoints Met

By Charles Gross

November 5, 12:21 PM

MoonLake Immunotherapeutics ((&ldquo, MoonLake&rdquo, , NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced positive top-line results

MLTX

Oppenheimer Maintains Outperform on Shopify. Price adjusts to $50.

Related Posts

GitLab Introduces TeamOps, A New Practice For All Work Environments – Remote, Hybrid And In-Office

Barclays Maintains Equal-Weight on Blueprint Medicines, Lowers Price Target to $58

What 10 Analyst Ratings Have To Say About Revolve Gr

Moonlake Immunotherapeutics Announced Landmark Phase 2 Results For Nanobody Sonelokimab In Active Psoriatic Arthritis; Primary Endpoint; Key Secondary Endpoints Met